Author:
Barrera-Penagos Viviana,Castellanos-Leguizamón Daniela,Hakim-Tawil José Antonio,Santivañez Juan José,Rodríguez-Urrego Paula A.,Hiromi López-Takegami Juan Carlos
Reference9 articles.
1. Immunotherapy in myeloproliferative diseases;Braun;Cells,2020
2. Aggressive merkel cell carcinoma after janus kinase inhibitor ruxolitinib for polycythemia vera;Rastrelli;In Vivo,2019
3. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis;Harrison;Leukemia,2016
4. Janus kinase inhibitors and non-melanoma skin cancer;Greif;Curr Treat Options Oncol,2021
5. Aggressive skin cancers occurring in patients treated with the janus kinase inhibitor ruxolitinib;Blechman;J Drugs Dermatol,2017